VERA VERA THERAPEUTICS INC

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics to Participate at Upcoming Investor Conferences

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.

Investor Conference Details:

  • Guggenheim Securities Healthcare Innovation Conference

    Format: Fireside Chat and 1x1s

    Webcast: Date: Wednesday, November 13, 2024

    Time: 9:30am EST

    Location: Boston, MA
  • 7th Annual Evercore ISI HealthCONx Conference

    Format: Fireside Chat and 1x1s

    Webcast: Date: Thursday, December 5, 2024

    Time: 7:55am EST

    Location: Coral Gables, FL

A replay of the webcast will be available for 90 days and can be accessed by visiting the “” section of the Vera Therapeutics website.

About Vera

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit .

For more information, please contact:

Investor Contact:

Joyce Allaire

LifeSci Advisors

212-915-2569

Media Contact:

Madelin Hawtin

LifeSci Communications



EN
08/11/2024

Underlying

VERAVERA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VERA THERAPEUTICS INC

 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera’s new Chief Legal Officer, under Vera’s 2024 Inducement Plan. The Compensation Committee approved the a...

9h / 13m 1 EN
 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. “We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and...

November 18, 2024 1 EN
 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in ...

November 11, 2024 1 EN
 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics Partners with University of Michigan on the NEPTUNE ...

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands the investigation of atacicept into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition; BRISBANE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company fo...

November 11, 2024 1 EN
 PRESS RELEASE
Free
VERA VERA THERAPEUTI...

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1sWebcast: Date:...

November 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch